capivasertib

Capivasertib is currently being tested as an oral small-molecule AKT inhibitor in clinical trials for breast cancer that is resistant to other drugs.

On November 16, 2023, the FDA approved Capivasertib (Truqap) in combination with fulvestrant (Faslodex) for the treatment of adult patients with locally advanced or metastatic, hormone receptor (HR)-positive, HER2-negative breast cancer who have 1 or more PIK3CA, AKT1, or PTEN alterations.

Capivasertib, a novel pyrrolopyrimidine derivative, has been studied as a potential treatment for Metastatic Breast Cancer. It is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) and has potential antineoplastic activity.

AstraZeneca’s capivasertib, when used with fulvestrant, has been granted approval by the FDA for the treatment of hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer in adults who have one or more biomarker alterations in PIK3CA, AKT1, or PTEN.

The results of Phase I studies showed that capivasertib exposure increased in a dose-dependent manner within the 80-800 mg dose range. The median time for capivasertib to reach maximum plasma concentration (tmax) was 2 hours, with the tablet formulation reaching tmax 1 hour earlier than the capsule formulation. The terminal half-life (t½) of capivasertib was approximately 10 hours.

With an IC50 of 8 nM, it hinders the phosphorylation of ATR-driven phosphorylated checkpoint kinase-1.

This outcome reaffirms that entrectinib is an effective medication for treating solid tumors or CNS tumors that have gene fusion involving NTRK1/2/3, ROS1, or ALK.

Cisplatin exerts its anticancer effects through various mechanisms, but its most widely accepted mechanism involves the creation of DNA lesions by interacting with purine bases on DNA. This interaction then activates multiple signal transduction pathways, ultimately leading to apoptosis.

Anthracycline drugs have a wide range of applications in cancer treatment, including leukemias, lymphomas, and various types of cancers such as breast, stomach, uterus, ovary, and lung cancer. Additionally, due to its origin, anthracycline is classified as an antibiotic, making it one of the antibiotics used specifically for cancer treatment.

The results of the CAPItello-291 study, a double-blind, phase III, randomised trial, demonstrated that combining the AKT inhibitor capivasertib with fulvestrant led to a notable increase in progression-free survival (PFS) for patients with advanced hormone receptor (HR)-positive, HER2-negative breast cancer that had advanced.

The uses of these compounds are under investigation and have not yet been approved by the U.S. Food and Drug Administration.

Belonging to the protein kinase B (AKT) inhibitor class of medications, Ipatasertib has the potential to halt the growth and eliminate tumor cells. Cisplatin, a chemotherapy utilized in this study, falls under the category of platinum-containing compounds.

Faslodex, also known as fulvestrant, is a medication that selectively downregulates estrogen receptors. It is prescribed for the treatment of advanced-stage breast cancer that is hormone receptor-positive and HER2-negative. It can be used alone or in combination with other targeted therapy medications.

Capivasertib (Truqap) has been approved by the FDA to be used in combination with fulvestrant (Faslodex) for treating adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. This is specifically for patients who have 1 or more PIK3CA, AKT1, or PTEN alteration, as detected by an FDA-approved test.

Olaparib (Lynparza®), a medication, specifically targets cancers that have mutations in the BRCA genes. It functions by inhibiting the molecule PARP, which prevents cancer cells from repairing their DNA. Consequently, the cancerous cells are unable to survive and die.

Capivasertib is administered orally in the form of tablets. The recommended dosage is 400 mg, which is equivalent to taking 2 tablets twice daily (BD). The medication is given on an intermittent weekly dosing schedule, specifically on Days 2 to 5 of Weeks 1, 2, and 3 within each 28-day treatment cycle. After completing the three weeks of treatment, there is a one-week break from taking the medication.

AstraZeneca discovered Capivasertib through a collaboration with Astex Therapeutics, which had previously collaborated with the Institute of Cancer Research and Cancer Research Technology Limited.

Procarbazine is classified as a specialty medication and a Limited Distribution Drug (LDD), which means it can only be obtained from specialty pharmacies and not from retail pharmacies such as CVS or Walgreens.

Clinicians who request and obtain an FDA-authorized single-patient emergency use IND (e-IND) can access Brincidofovir from the SNS for the treatment of mpox.

Alpelisib (Vijoice, Novartis Pharmaceuticals) has been granted accelerated approval by the Food and Drug Administration on April 5, 2022. This approval is for the treatment of severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in adult and pediatric patients aged two years and older who need systemic therapy.

Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant has been approved by the Food and Drug Administration on November 16, 2023. This approval is specifically for adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer and have one or more PIK3CA/AKT1/ mutations.

Trastuzumab, also known as Herceptin, Herzuma, and Ontruzant, is a targeted cancer medication used to treat early and advanced breast cancer, advanced stomach cancer, and cancer of the gastroesophageal junction.

According to the data, the FDA has granted approval for capivasertib plus fulvestrant on November 16, 2023. This treatment is intended for patients who have 1 or more PIK3CA, AKT1, or PTEN alterations and have experienced progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence within 12 months of treatment.

Toremifene is primarily sold under the brand name Fareston.

It is utilized in the treatment of various types of cancers, either as a standalone medication or in combination with other cancer drugs like bevacizumab.

Fareston (toremifene citrate) is a medication that acts as both an estrogen agonist and antagonist. It works by preventing estrogen from reaching cancer cells, thereby slowing down the growth of metastatic breast cancer, which is cancer that has spread from the original tumor.

Fulvestrant, also known as Faslodex, is a medication used to treat breast cancer.

Trodelvy, also known as sacituzumab govitecan-hziy, is prescribed for the treatment of hormone receptor-positive and hormone receptor-negative, HER2-negative breast cancer that is unresectable and has spread locally or metastasized. This medication is specifically used for patients who have already undergone at least two other systemic treatments.

Diarrhea, skin rash, and high blood sugar.

Nerve Problems (Peripheral Neuropathy) and Organ-Related Inflammation: The Role of Immunotherapy in Pain Management. Addressing Sexual Health Issues in Men.

Acute Myeloid Leukemia (AML) is a rare but potentially life-threatening adverse reaction. Alopecia, which causes long-term or permanent hair loss, is another side effect. Cardiotoxicity, a rare occurrence, can lead to heart damage. Myelodysplastic Syndrome, a very rare disease, is also associated with AML.

Symptoms: Agitation, bladder pain, bleeding of the gums, bloody or cloudy urine, bone pain, burning, itching, and pain in hairy areas with pus at the root of hair, burning, tingling, numbness or pain in the hands, arms, feet, or legs, coma.

While docetaxel is primarily utilized for cancer treatment, there is a rare possibility that it could elevate the risk of developing other types of cancer, such as acute myeloid leukemia (AML), Non-Hodgkin’s Lymphoma, or kidney cancer. It is important to note that these occurrences may manifest months or even years after the completion of treatment.

The AKT1 E17K mutation is frequently found in breast cancer, colorectal cancer, lung cancer, and ovarian cancer. It primarily activates the PI3K/Akt signaling pathway. The E17K hotspot is the most distinctive mutation of the AKT1 gene.

Although anastrozole is generally considered safe for long-term use, it is important for your specialist team to closely monitor your health. This is because anastrozole decreases the levels of estrogen in your body, which is necessary for maintaining strong and healthy bones.

Cancer treatments can lead to a variety of side effects such as fatigue, loss of appetite, and depression. The National Cancer Institute and the American Cancer Society provide information on these issues and offer advice on how to manage or prevent them.

Symptoms include difficulties with blood clotting and wound healing, high blood pressure, fatigue, mouth sores, nail abnormalities, hair discoloration, and skin issues such as rashes or dryness.

Tamoxifen can elevate the likelihood of developing uterine cancers, such as endometrial cancer and uterine sarcoma, due to its estrogen-like effects in the uterus. Additionally, it is associated with a higher risk of endometrial pre-cancers. This increased risk primarily affects women aged 50 and above, rather than younger women.